This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
bluebird bio Croissance future
Future contrôle des critères 2/6
bluebird bio devrait augmenter son chiffre d'affaires de 21.9% par an. Le BPA devrait augmenter de de 59.6% par an.
Informations clés
n/a
Taux de croissance des bénéfices
59.56%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.3% |
| Taux de croissance des recettes | 21.9% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 16 May 2025 |
Mises à jour récentes de la croissance future
Recent updates
Seeking Alpha • May 25
High Noon For bluebird
Summary bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival bidder, Ayrmid, previously offered $4.50 plus the same CVR, but financing delays stalled a superior deal. If Ayrmid returns with a $6.50 all-cash offer before Tuesday, shareholders could see a bidding war; time is critical. At ~$5 per share, risk/reward is highly asymmetric—downside is limited, upside could be significant if a bidding war emerges. Read the full article on Seeking Alpha
Nouveau récit • Apr 08
Patient Starts And Capacity Expansion Will Achieve Breakeven
Sustained patient demand and operational efficiency improvements are poised to enhance revenue growth and financial stability by driving cash flow breakeven.Article d’analyse • Jan 04
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38%
bluebird bio, Inc. ( NASDAQ:BLUE ) shareholders won't be pleased to see that the share price has had a very rough...Article d’analyse • Nov 15
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 1.3x bluebird bio, Inc. ( NASDAQ:BLUE ) may be sending very bullish signals...Seeking Alpha • Sep 26
bluebird bio: Scientific Success And Financial Success, And The Gap Between
Summary Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This despite getting three gene therapies on the market. Two of bluebird bio’s gene therapies, Zentego and Lyfgenia, compete with Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics, which is approved for basically the same patient populations. The company is cutting staff, especially in R&D, in order to focus on commercial operations. But whether that will work is unknown. Read the full article on Seeking AlphaSeeking Alpha • Jun 27
bluebird bio's Flight Through Financial Fog And Fierce Rivals
Summary bluebird bio, Inc. stock plummeted by 73% amid financial struggles and operational hurdles post FDA approval of their gene therapy Lyfgenia. The company faces intense competition from CRISPR Therapeutics' Casgevy, which benefits from stronger resources and a faster market rollout. Recent financial disclosures are incomplete, obscuring a clear view of bluebird's financial health and prolonging investor uncertainty. Maintain a sell recommendation on bluebird bio due to substantial financial and operational risks, with a cautious note on potential high volatility. Read the full article on Seeking AlphaSeeking Alpha • Mar 23
bluebird bio Is Priced Below IP Value
Summary bluebird bio's stock price has dropped 64% due to safety warnings and high pricing for their sickle cell treatment. The company's intellectual property alone suggests a potential sale value of $300-320 million, higher than its current market cap of $280 million. bluebird bio has extended its cash runway and has the potential to achieve profitability within the next year. Read the full article on Seeking AlphaSeeking Alpha • Jan 25
Bluebird Bio: Innovative Therapies, Monetary Setbacks
Summary More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming. The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges. High treatment costs, limited patient base, outsourced production, long-term follow-up studies, and intensifying competition are all factors that obscure BLUE's path to profitability. Read the full article on Seeking AlphaArticle d’analyse • Oct 13
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Article d’analyse • Jul 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Oct 04
Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Real Endpoints said it is collaboration with bluebird bio (NASDAQ:BLUE) to provide multiple health plans with access to an outcomes-based agreement for β-thalassemia gene therapy Zynteglo through the Real Endpoints (RE) Marketplace. Zynteglo, which is approved to treat patients with beta-thalassemia who require regular blood transfusions, is priced at $2.8M for a one-time therapy, making it the most expensive treatment in history. Real noted that these plans cover ~16M people in the U.S. Through a single contract, the plans in RE Marketplace can take immediate advantage of bluebird's agreement, which offers rebates of up to 80% if treatment with Zynteglo does not enable a patient to achieve and maintain transfusion independence in two years following therapy, Real said in an Oct. 4 press release. "The plans in RE Marketplace are thrilled to be able to easily access bluebird’s innovative risk-sharing agreement, which speeds the delivery of both clinical and economic innovations," said Real's Chief Clinical Officer Jane Barlow. BLUE +2.77% to $6.30 premarketSeeking Alpha • Sep 26
Bluebird bio names interim finance chief
Gene therapy developer bluebird bio, Inc. (NASDAQ:BLUE) has named Katherine Breedis, formerly the Chief Financial Officer Consultant at Danforth Advisors, as the company’s interim Chief Financial Officer replacing the outgoing CFO Jason Cole. Ms. Breedis has also been named as BLUE’s principal financial officer and principal accounting officer, and her appointments will take effect on Oct. 14 when Mr. Cole departs. Ms. Breedis, who has worked as a CFO consultant for Danforth since Jul. 2021, served as a consultant to BLUE after the company struck a consulting agreement with the advisory firm in May. Mr. Cole’s departure came less than a month after the FDA approved BLUE’s β-thalassemia therapy Zynteglo in August, making it the priciest treatment in history at the time.Seeking Alpha • Sep 19
Bluebird bio jumps 17% on FDA approval of new gene therapy
The commercial-stage biotech bluebird bio, Inc. (NASDAQ:BLUE) added ~17% pre-market Monday after the company announced the FDA approval of its gene therapy Skysona to address the impact of a rare neurodegenerative disease called cerebral adrenoleukodystrophy (CALD). According to the late Friday press release, the drug, also known as elivaldogene autotemcel (eli-cel), will be indicated in the U.S. to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active CALD. With the FDA approving Skysona under the agency’s accelerated approval pathway, BLUE has agreed to deliver long-term clinical data on the treatment to the regulator, including data from an ongoing long-term follow-up study and commercially treated patients. The company expects the drug to be commercially available by the end of 2022 at a list price of $3.0M. Concurrently, BLUE confirmed that the FDA had lifted the clinical hold on the eli-cel development program. In August, Cambridge, Massachusetts-based biotech won FDA approval for another gene therapy known as Zynteglo for β-thalassemia which it priced at $2.8M.Seeking Alpha • Sep 12
bluebird bio' chief strategy and financial officer to depart
Jason Cole, chief strategy and financial officer of bluebird bio (NASDAQ:BLUE), plans to leave the firm, effective Oct 14, 2022, to pursue new career opportunities. Mr. Cole spent 8.5 years at bluebird, serving in multiple roles including general counsel/chief legal officer, chief operating & legal officer and chief business officer. He took the chief strategy and financial officer role in Mar 2022, leading changes to stabilize the firm's financial position and strengthen its balance sheet. bluebird (BLUE) has initiated an external search for its next CFO. In the meantime, Katherine Breedis, an experienced business and financial executive from Danforth Advisors, is expected to serve as interim CFO. Cole is expected to continue to consult with the company on corporate strategy through April 2023.Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2027 | 277 | N/A | N/A | N/A | 1 |
| 12/31/2026 | 225 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 227 | -150 | N/A | N/A | 4 |
| 3/31/2025 | 104 | -200 | -230 | -229 | N/A |
| 12/31/2024 | 84 | -241 | -263 | -260 | N/A |
| 9/30/2024 | 53 | -293 | -271 | -264 | N/A |
| 6/30/2024 | 55 | -319 | -254 | -245 | N/A |
| 3/31/2024 | 46 | -301 | -248 | -238 | N/A |
| 12/31/2023 | 29 | -212 | -244 | -235 | N/A |
| 9/30/2023 | 22 | -63 | -209 | -200 | N/A |
| 6/30/2023 | 9 | -52 | -236 | -227 | N/A |
| 3/31/2023 | 4 | -89 | -276 | -262 | N/A |
| 12/31/2022 | 4 | -230 | -329 | -316 | N/A |
| 9/30/2022 | 5 | -431 | -447 | -436 | N/A |
| 6/30/2022 | 6 | -507 | -525 | -506 | N/A |
| 3/31/2022 | 5 | -563 | -574 | -558 | N/A |
| 12/31/2021 | 4 | -563 | -659 | -636 | N/A |
| 9/30/2021 | -238 | -573 | -680 | -651 | N/A |
| 6/30/2021 | -220 | -614 | -678 | -653 | N/A |
| 3/31/2021 | -21 | -480 | -493 | -468 | N/A |
| 12/31/2020 | N/A | -561 | -499 | -470 | N/A |
| 9/30/2020 | 250 | -642 | -509 | -474 | N/A |
| 6/30/2020 | 240 | -653 | -493 | -439 | N/A |
| 3/31/2020 | 54 | -828 | -684 | -616 | N/A |
| 12/31/2019 | N/A | -555 | -641 | -564 | N/A |
| 9/30/2019 | 54 | -715 | -611 | -535 | N/A |
| 6/30/2019 | 57 | -655 | -569 | -496 | N/A |
| 3/31/2019 | 51 | -605 | -526 | -459 | N/A |
| 12/31/2018 | 55 | -556 | N/A | -413 | N/A |
| 9/30/2018 | 40 | -524 | N/A | -379 | N/A |
| 6/30/2018 | 36 | -457 | N/A | -361 | N/A |
| 3/31/2018 | 45 | -382 | N/A | -314 | N/A |
| 12/31/2017 | 35 | -336 | N/A | -281 | N/A |
| 9/30/2017 | 33 | -290 | N/A | -254 | N/A |
| 6/30/2017 | 27 | -288 | N/A | -237 | N/A |
| 3/31/2017 | 11 | -276 | N/A | -228 | N/A |
| 12/31/2016 | 6 | -264 | N/A | -190 | N/A |
| 9/30/2016 | 6 | -239 | N/A | -154 | N/A |
| 6/30/2016 | 6 | -205 | N/A | -143 | N/A |
| 3/31/2016 | 9 | -198 | N/A | -111 | N/A |
| 12/31/2015 | 14 | -167 | N/A | -98 | N/A |
| 9/30/2015 | 19 | -139 | N/A | -81 | N/A |
| 6/30/2015 | 24 | -113 | N/A | -73 | N/A |
| 3/31/2015 | 25 | -63 | N/A | -72 | N/A |
| 12/31/2014 | 25 | -49 | N/A | -60 | N/A |
| 9/30/2014 | 25 | -37 | N/A | -49 | N/A |
| 6/30/2014 | 25 | -26 | N/A | -38 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de BLUE est supérieure au taux d'épargne ( 2.9% ).
Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de BLUE devraient croître plus rapidement que le marché US
Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de BLUE devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de BLUE ( 21.9% par an) devrait croître plus rapidement que le marché US ( 11.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de BLUE ( 21.9% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de BLUE devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2025/05/30 07:06 |
| Cours de l'action en fin de journée | 2025/05/30 00:00 |
| Les revenus | 2025/03/31 |
| Revenus annuels | 2024/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
bluebird bio, Inc. est couverte par 21 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Vincent Chen | Bernstein |
| Matthew Luchini | BMO Capital Markets Equity Research |